BioXcel Therapeutics
BTAI
BTAI
96 hedge funds and large institutions have $274M invested in BioXcel Therapeutics in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
3% less capital invested
Capital invested by funds: $283M → $274M (-$9.19M)
21% less call options, than puts
Call options by funds: $3.46M | Put options by funds: $4.4M
Holders
96
Holding in Top 10
–
Calls
$3.46M
Puts
$4.4M
Top Buyers
| 1 | +$5.62M | |
| 2 | +$2.01M | |
| 3 | +$1.69M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.16M |
| 5 |
Jane Street
New York
|
+$1.14M |
Top Sellers
| 1 | -$30.7M | |
| 2 | -$1.3M | |
| 3 | -$1.12M | |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$609K |
| 5 |
Morgan Stanley
New York
|
-$495K |